NRSN SEC Filing News — NeuroSense Therapeutics Ltd.

Latest SEC filings for NeuroSense Therapeutics Ltd. (NRSN) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-06-17.

Market Cap: $5.8M CIK: 1875091
5
Total Filings
2
Bullish Classifications
0
Bearish Classifications
5
Insider Transactions
0
Material Events (8-K)
0
Periodic Reports
Rule-based classifications for NRSN currently lean bullish. Of the 5 displayed SEC filing records, 2 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 5 insider transactions (Form 4) in this period.
NRSN Filing Activity Snapshot 2026-03-30 — 2026-06-17
Insider Transactions (Form 4)
2 buys vs 0 sells
Net insider buying in this period — more purchases than sales reported.
Largest Form 144 Filing
$200.0K
Ben-Noon Alon (Chief Executive Officer) · 2026-06-17
250,000 shares · Form 4
Insider Transactions 5 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 5 filings in this group are Form 4s for NeuroSense Therapeutics Ltd.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 5 insider filings shown, the breakdown is 3 compensation award and 2 open-market purchase. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×3
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×2
The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Form 4 Open-market purchase Insider Buying 2026-06-17

NRSN insider Ben-Noon Alon (Chief Executive Officer) bought 250,000 shares (~$200.0K)

Ben-Noon Alon, listed as Chief Executive Officer at NeuroSense Therapeutics Ltd., reported an open-market purchase of 250,000 NRSN shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 250,000 $0.80 $200.0K
Filing: Form 4 (Insider Transaction) Insider: Ben-Noon Alon (Chief Executive Officer) Shares: 250,000 Est. Value: $200.0K
Form 4 Open-market purchase Insider Buying 2026-06-17

NRSN insider Eisenberg Or (Chief Financial Officer) bought 250,000 shares (~$200.0K)

Eisenberg Or, listed as Chief Financial Officer at NeuroSense Therapeutics Ltd., reported an open-market purchase of 250,000 NRSN shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 250,000 $0.80 $200.0K
Filing: Form 4 (Insider Transaction) Insider: Eisenberg Or (Chief Financial Officer) Shares: 250,000 Est. Value: $200.0K
Form 4 Compensation award Tax / Compensation Filing 2026-04-01

NRSN insider Form 4 filed for equity award, exercise, or tax withholding

Eisenberg Or (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 200,000 — —
Filing: Form 4 (Insider Transaction) Insider: Eisenberg Or (Chief Financial Officer) Shares: 200,000
Form 4 Compensation award Tax / Compensation Filing 2026-03-30

NRSN insider Form 4 filed for equity award, exercise, or tax withholding

Russek-Blum Niva (Chief Technology Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 200,000 — —
Filing: Form 4 (Insider Transaction) Insider: Russek-Blum Niva (Chief Technology Officer) Shares: 200,000
Form 4 Compensation award Tax / Compensation Filing 2026-03-30

NRSN insider Form 4 filed for equity award, exercise, or tax withholding

Binder Hagit (General Manager) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 200,000 — —
Filing: Form 4 (Insider Transaction) Insider: Binder Hagit (General Manager) Shares: 200,000

How we classify NeuroSense Therapeutics Ltd.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on NRSN. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — NRSN SEC Filings

More Tools for NRSN

Want deeper NRSN analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the NRSN stock analysis page.

NRSN Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer